Well, good morning everyone, and thank you for joining us. Before I talk about our outlook for 2024, let me first thank the entire CareTrust team for their great work in '23. It was a year of growth for the company on several fronts. Internally, the team is more capable, creative, and collaborative than ever before. It's a real privilege to work every day with this team. I also want to thank our operators, who we consider by and large to be among the very best in the business. It's their relentless dedication to their staff, residents, and patients, that is making this world a better place and we're honored to help them expand their influence. Now, this time last year, we started to sense a window of opportunity open to return to external growth in a meaningful way, as the bulk of our repositioning work concluded and the credit market tightened. Sellers and brokers prioritized the execution certainty that we bring to the table and deal flow picked up. I'm very pleased to report $288 million of new investments last year at a blended stabilized yield of 9.8%. And as good as those numbers are, maybe more exciting is the fact that we ended the year with the full $600 million available on our line of credit and just under $300 million of cash on the balance sheet. We have never had this amount of dry powder. Why? Because we expect 2024 to be a strong year of investments, and we positioned ourselves accordingly. As we've reported, we've kicked off the year with $63 million of new investments, $52 million of that are secured loans. Let me reiterate briefly our philosophy for lending. Loans in this space are generally shorter terms, somewhere between two to five years, which can cause some lumpiness to earnings as paybacks occur. So for us, in order to lend, three criteria must be met. First, the investment will be run by a top-shelf operator with whom we want to start or expand our relationship. Second, the investment meets our historic underwriting criteria and is accretive in year one. And third, the transaction provides for a path to future real estate acquisitions, either built into the deal directly or simply from the relationship. Since 2022, and not including the loans announced this week, we've made about $170 million worth of loans, each one meeting these criteria. Now here's what's remarkable. As we examine the real estate acquisitions made last year and those in our current pipeline, we count over $300 million, largely off-market deals, that are a direct result of the relationships with the investors, borrowers, and operators, that we established from that strategic planning activity. That is a virtuous cycle we will continue to feed. James will give you more color on the investments in the quarter and year-to-date and on the current pipeline, which as we sit here today, is about $250 million, not including larger deals that we regularly review. Now, turning to the portfolio, you'll see in the supplemental, lease coverage slightly improved overall. Occupancy for the quarter for both skilled nursing and seniors housing was basically flat compared to Q3. And I wanted to follow up on a couple of operators. The transition of two Eduro facilities to another operator today is on track for a March 1 transition. Eduro's pro forma lease coverage, excluding those two facilities goes from just under 1 times to just north of it. Also, we're still under contract to sell the portfolio of 11 skilled nursing assets with negative EBITDA, primarily in the Midwest. Understandably, financing has been challenging, but the buyer continues to make good-faith efforts that lead us to believe a deal will get done. Finally, we're pleased to issue guidance again. Bill will walk you through our several assumptions, that result in 2024 normalized FFO per share in the range of $1.43 to $1.45. Please remember that when we issue guidance, we do not include assumptions for new investments for a couple of reasons. First, due to regulatory and licensing requirements that always accompany these transactions, timing of deals can be tricky. And second, we do not set arbitrary growth targets, so that we can retain our customary discipline model for growth. Now, before I hand it over to James to talk about investments, let me just summarize our outlook for 2024 like this. We have a favorable cost of capital that allows for accretive investments. We have a balance sheet that provides enormous flexibility and capacity. And we have a macro environment that has opened a window of opportunity as long as the credit market remains challenging, which leads me to believe that 2024 should be a strong year for external growth for CareTrust. With that, James will talk to our recent investment activity and pipeline. James?